Arbor Investment Advisors LLC Buys 500 Shares of Johnson & Johnson (NYSE:JNJ)

Arbor Investment Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 19.0% during the fourth quarter, HoldingsChannel reports. The firm owned 3,130 shares of the company’s stock after purchasing an additional 500 shares during the quarter. Arbor Investment Advisors LLC’s holdings in Johnson & Johnson were worth $491,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Hibernia Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $27,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $37,000. Tower View Wealth Management LLC lifted its position in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 165 shares during the period. Keener Financial Planning LLC purchased a new position in Johnson & Johnson in the fourth quarter worth about $40,000. Finally, Creative Capital Management Investments LLC raised its holdings in Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 28th. Finally, Raymond James lifted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $144.45 on Wednesday. The firm has a 50 day moving average of $156.80 and a 200 day moving average of $155.82. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $348.09 billion, a price-to-earnings ratio of 10.46, a price-to-earnings-growth ratio of 2.48 and a beta of 0.53. Johnson & Johnson has a 12-month low of $143.39 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.68 earnings per share. On average, research analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be given a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Insiders Place Their Bets

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.